Precigen Shareholders Expand Incentive Plan, Reaffirm Governance
Precigen shareholders approved an expansion of the company's 2023 Omnibus Incentive Plan by adding 7 million shares for equity awards at their Annual Meeting on June 18, 2026. This decision reflects continued support for equity-based compensation as a talent strategy, despite potential future dilution. Shareholders also re-elected all nominated directors, ratified Deloitte & Touche LLP as the independent auditor, and supported an advisory resolution on executive pay, signaling alignment with the company's current governance practices.
Price to sales forward of Precigen, Inc. – NASDAQ:PGEN
This article provides a financial data point for Precigen, Inc. (NASDAQ: PGEN), specifically its forward price-to-sales ratio. The page indicates that the market is currently closed, and no trades have been executed. It appears to be a data-only page from TradingView, offering a snapshot of a single financial metric for the company.
Precigen (PGEN) investors back 7M-share incentive pool and all board picks
Precigen, Inc. stockholders approved an amendment to the 2023 Omnibus Incentive Plan, increasing available shares for equity awards by 7 million. They also re-elected nine directors, ratified Deloitte & Touche LLP as the independent auditor for 2026, and passed a non-binding advisory vote on executive compensation. All management proposals received significant support from shareholders.
Clearfield And 2 Insider Picks For Strong Growth
This article identifies three U.S. growth companies with high insider ownership: Clearfield (CLFD), BillionToOne (BLLN), and Precigen (PGEN). The U.S. market has seen a 2.3% decline recently, but is up 21% over the past year with 19% annual earnings growth forecasted. The article highlights each company's financial performance, growth potential, insider ownership percentages, and key strategic developments, suggesting they could be appealing for investors seeking robust opportunities despite some being potentially overvalued.
Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS Therapy - What's Changed
Precigen (PGEN) shares rose 12.1% following its PAPZIMEOS therapy receiving FDA orphan drug exclusivity, granting seven years of market protection for adult recurrent respiratory papillomatosis. This exclusivity strengthens the therapy's market position, especially with data showing many patients remain surgery-free for at least three years, aiming to reshape Precigen's investment narrative around growth and risk. The company's Q1 2026 results showed early revenue traction (US$23.25 million) but also highlighted a net loss of US$7.93 million, indicating a strong dependence on scaling PAPZIMEOS to achieve profitability and reduce financing risks.
Precigen (PGEN) Is Up 12.1% After Orphan Exclusivity Win for PAPZIMEOS Therapy - What's Changed
Precigen (PGEN) secured seven years of FDA orphan drug exclusivity for its PAPZIMEOS therapy for adult recurrent respiratory papillomatosis, strengthening its market position. This exclusivity, supported by clinical data, has positively impacted Precigen's stock and investment outlook; however, the company still faces near-term execution risks regarding market adoption and achieving cash flow breakeven despite promising Q1 2026 revenue. The article highlights both the significant upside potential and the financial challenges Precigen must navigate.
Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) stock is under scrutiny after the FDA granted orphan drug exclusivity for PAPZIMEOS, which could significantly impact its commercial runway. Despite a strong recent share price performance, its high price-to-book ratio suggests it's overvalued based on current assets, but a discounted cash flow model indicates it might be undervalued. Investors are advised to consider both the company's early-stage losses and its future potential driven by its gene and cell therapy platforms.
Precigen (PGEN) Stock Could Be 79% Undervalued After FDA Exclusivity Win
Precigen (PGEN) has received orphan drug exclusivity for PAPZIMEOS from the FDA, leading to a significant rally in its stock price. Despite a high Price-to-Book ratio of 84.9x suggesting overvaluation based on current assets, a Discounted Cash Flow (DCF) model indicates the stock could be 79% undervalued. Investors are faced with conflicting signals regarding the company's valuation, which relies heavily on future potential in gene and cell therapy rather than current fundamentals.
Precigen (PGEN) Secures FDA Orphan Drug Exclusivity for PAPZIMEOS
Precigen (PGEN) obtained FDA orphan drug exclusivity for PAPZIMEOS, a precision medicine for adult recurrent respiratory papillomatosis (RRP), safeguarding its market exclusivity until August 2032. Developed with the AdenoVerse platform, PAPZIMEOS targets HPV 6 and 11, the causes of RRP, and has demonstrated long-term effectiveness in clinical trials. The article also suggests that while PGEN has potential, other AI stocks might offer greater upside with less risk.
PGEN: All proposals, including board elections and compensation, passed overwhelmingly without shareholder questions
Precigen, Inc. (PGEN) held its 2026 AGM where all proposals, including board elections, auditor ratification, executive compensation, and an incentive plan amendment, passed with overwhelming support. There were no shareholder questions or comments received during the meeting. This information is based on an AI-generated summary of the AGM audio transcript.
Precigen Inc (PGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates
Precigen Inc (PGEN) has an earnings forecast score of 7.33, placing it 103rd out of 157 in the Pharmaceuticals industry. Analysts have set an average price target of $8.50 for PGEN, with a "Buy" trend based on ratings from 3 analysts. The company's expected revenue for the next quarter is $27.84 million, and its EPS for the previous quarter was -$0.07, with an expectation of -$0.01 for the next quarter.
H.C. Wainwright Remains a Buy on Precigen (PGEN)
H.C. Wainwright has reiterated a Buy rating on Precigen (PGEN) with a $14 price target, following positive long-term follow-up data presented for the company's treatment PAPZIMEOS at a major oncology conference. The data showed durable complete responses in patients with recurrent respiratory papillomatosis, with many responders maintaining effects for over three years. The firm highlights durability as a key factor in its continued positive outlook for the clinical-stage biopharmaceutical company.
H.C. Wainwright Remains a Buy on Precigen (PGEN)
H.C. Wainwright has reiterated a Buy rating on Precigen (PGEN) with a $14 price target following positive long-term follow-up data from their PAPZIMEOS treatment for recurrent respiratory papillomatosis. The data, presented at a major oncology conference, highlighted strong durability, with 83% of responders showing ongoing complete response for at least 36 months. Precigen, a clinical-stage biopharmaceutical company, is focused on developing gene and cell therapies.
Why Precigen (PGEN) Is Up 24.6% After FDA Orphan Exclusivity Win For PAPZIMEOS
Precigen (PGEN) shares rose 24.6% after the FDA granted orphan drug exclusivity to its HPV-targeted immunotherapy, PAPZIMEOS, for recurrent respiratory papillomatosis (RRP). This exclusivity, along with strong long-term data presented at ASCO, reinforces PAPZIMEOS's position as a potential standard of care. The company's investment narrative and future revenue potential are strengthened, but risks related to real-world durability, pricing pressure, and achieving cash flow breakeven remain.
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Precigen's PAPZIMEOS has received Orphan Drug Exclusivity from the FDA, extending its market exclusivity for recurrent respiratory papillomatosis (RRP) treatment until August 2032. This exclusivity, combined with the company's patent portfolio, strengthens the drug's market protection and revenue potential. Early long-term data from a pivotal study also shows encouraging durability, with 83% of complete responders maintaining their response for at least 36 months without additional RRP treatment.
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Precigen Inc. has received Orphan Drug Exclusivity from the FDA for its RRP treatment, PAPZIMEOS, extending market protection until August 2032. This exclusivity, combined with long-term clinical data showing sustained complete responses in patients, strengthens the drug's market position and potential as a new standard of care for recurrent respiratory papillomatosis. PAPZIMEOS offers an alternative to repeated surgeries by training the immune system to combat the HPV viruses responsible for the disease.
Why Precigen (PGEN) Is Up 24.6% After FDA Orphan Exclusivity Win For PAPZIMEOS
Precigen (PGEN) saw a 24.6% increase after the FDA granted orphan drug exclusivity to its HPV-targeted immunotherapy, PAPZIMEOS, for recurrent respiratory papillomatosis (RRP). This exclusivity, along with positive long-term data, strengthens PAPZIMEOS's market position and potential as a standard of care. Despite positive revenue and earnings forecasts, investment in Precigen remains contingent on PAPZIMEOS's real-world performance, pricing power, and the company's path to cash flow breakeven.
Precigen receives seven-year exclusivity for rare disease drug
Precigen Inc. (NASDAQ:PGEN) has been granted orphan drug exclusivity by the FDA for its recurrent respiratory papillomatosis treatment, PAPZIMEOS, securing market exclusivity until August 2032. This development led to a significant jump in Precigen shares and reflects investor confidence in the drug's commercial prospects and the company's strong financial performance, including exceeding Q1 2026 earnings and revenue expectations. Analysts have also reiterated "Buy" ratings with price targets between $11 and $14.
Precigen gains 7 year FDA orphan drug exclusivity
Precigen (NASDAQ: PGEN) has secured seven-year FDA orphan drug exclusivity for its PAPZIMEOS treatment for adult recurrent respiratory papillomatosis (RRP), extending market protection through August 2032. This designation prevents similar drugs from being approved for the same indication. The decision was supported by long-term study data showing 83% of complete responders maintained their health for 36 months or more without additional therapy.
PAPZIMEOS keeps 83% of RRP complete responders surgery-free 3+ years
Precigen's PAPZIMEOS has received FDA orphan drug exclusivity for recurrent respiratory papillomatosis (RRP), blocking similar drug approvals for seven years and extending market exclusivity through August 2032. Long-term pivotal study data show that 83% of complete responders maintained their responses for at least 36 months without additional RRP treatment, with no new safety events reported. This regulatory advantage and encouraging efficacy data position PAPZIMEOS as a new standard of care for RRP, a disease historically managed with repeated surgeries.
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Precigen Inc. (NASDAQ:PGEN) has been granted orphan drug exclusivity by the FDA for its RRP treatment, PAPZIMEOS™, extending its market protection until August 2032. This exclusivity, combined with long-term clinical data presented at ASCO, which showed sustained complete responses in RRP patients, strengthens the product's market value and therapeutic impact. PAPZIMEOS™ offers a new standard of care for recurrent respiratory papillomatosis, reducing the need for repeated surgeries.
5 Best Penny Stocks That Could Skyrocket in 2026
This article highlights Precigen, Inc. (NASDAQ: PGEN) as a promising penny stock. H.C. Wainwright reiterated a Buy rating and a $14 price target after the company presented positive long-term follow-up data for its PAPZIMEOS treatment at an oncology conference. The data showed impressive sustained complete responses in patients with recurrent respiratory papillomatosis, validating the treatment's durability and Precigen's outlook as a clinical-stage biopharmaceutical company.
Precigen (PGEN) Stock After PAPZIMEOS Approval And Exclusivity What The Valuation Signals Suggest
Precigen (PGEN) has drawn attention due to PAPZIMEOS receiving full FDA approval and seven-year market exclusivity, which has led to a significant increase in its stock price over the past year. Despite a strong stock performance and a DCF model suggesting the stock is undervalued at $23.88 per share compared to its current price of $4.53, there are concerns regarding ongoing net losses and a high P/B ratio of 79.8x. Investors are advised to consider both the upside potential and risks given these mixed valuation signals.
Precigen (PGEN) Stock After PAPZIMEOS Approval And Exclusivity What The Valuation Signals Suggest
Precigen (PGEN) has drawn attention following the full FDA approval and seven-year market exclusivity for PAPZIMEOS, a therapy for adult recurrent respiratory papillomatosis, and updated long-term data for the treatment. Despite a significant 3x stock price increase over the last year, a Discounted Cash Flow (DCF) model suggests the stock is undervalued at $23.88 per share compared to its current price of $4.53. However, the Price-to-Book (P/B) ratio of 79.8x, significantly higher than the industry average, indicates potential overvaluation or strong market confidence.
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation (RRPF) are collaborating to recognize the third annual International RRP Awareness Day, focusing on elevating the voices of patients, caregivers, and healthcare providers affected by recurrent respiratory papillomatosis (RRP). This year's campaign highlights the daily realities of RRP and the significance of the first FDA-approved treatment for adults with the disease, developed by Precigen. The initiative aims to raise awareness, support the RRP community, and underscore the need for continued understanding and scientific progress for this rare, debilitating condition.
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Precigen and the Recurrent Respiratory Papillomatosis Foundation (RRPF) are collaborating for the third annual International RRP Awareness Day on June 11, 2026. This year's campaign, featured on rrpawareness.org, focuses on sharing the voices and experiences of patients, caregivers, and healthcare providers affected by recurrent respiratory papillomatosis (RRP). The initiative aims to raise awareness for RRP, a rare and debilitating disease, and follows the FDA approval of Precigen's HPV-specific immunotherapy, the first and only approved treatment for adults with RRP.
Precigen (NASDAQ:PGEN) Share Price Crosses Below 200-Day Moving Average - What's Next?
Precigen's (NASDAQ:PGEN) stock price has fallen below its 200-day moving average, signaling potential technical weakness. While analysts' views are mixed, with a consensus "Hold" rating despite some increased price targets, the company recently beat earnings expectations. Insider sales by the CEO and CFO to cover tax obligations were also noted.
Can PAPZIMEOS Durability Data Redefine Precigen’s (PGEN) Long-Term Revenue and Immunotherapy Narrative?
Precigen's PAPZIMEOS, a fully FDA-approved immunotherapy for recurrent respiratory papillomatosis, has shown sustained complete responses and no new safety issues in long-term follow-up data. This durability data supports PAPZIMEOS's role as a surgery-sparing standard, underpinning Precigen's investment narrative. However, the company still faces significant execution risks related to uptake, pricing, and cash flow, as highlighted by its Q1 2026 financials.
Have Precigen Insiders Been Selling Stock?
Precigen's President recently sold US$520k worth of stock, though this was a small percentage of her holding. Over the last year, insiders have sold significantly more stock than they purchased, with the Executive Chairman selling US$7.7m worth of shares. Despite high insider ownership, the substantial insider selling raises caution for potential investors.
Have Precigen Insiders Been Selling Stock?
Precigen (NASDAQ: PGEN) has seen recent insider selling, with President Helen Sabzevari selling US$520k worth of stock and Executive Chairman Randal Kirk selling US$7.7m over the last year. While insiders purchased 60.22k shares, they divested a significantly larger 4.82m shares in the past year, largely at prices below the current market value. Despite a healthy 12% insider ownership, these selling trends raise some caution for potential investors.
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock
Precigen CFO Harry Thomasian Jr. sold $182,614 worth of company stock to cover tax obligations related to restricted stock units. Despite a 229% stock return over the past year, InvestingPro suggests the shares may be overvalued. This transaction follows Precigen's strong Q1 2026 earnings and FDA orphan drug exclusivity for its treatment PAPZIMEOS.
Precigen COO Rutul R Shah sells $186,185 in common stock
Precigen's COO, Rutul R. Shah, sold 42,703 shares of the company's common stock for $186,185 to cover tax obligations from vested restricted stock units. Despite this insider sale, Precigen shares have seen a 229% return over the past year. The company recently reported strong Q1 2026 earnings and received orphan drug exclusivity for PAPZIMEOS from the FDA.
PRECIGEN (PGEN) CCO sells 30,272 shares in tax-related transaction
PRECIGEN's Chief Commercial Officer, Phil Tennant, sold 30,272 shares of common stock at $4.36 per share in a sell-to-cover transaction on May 28, 2026. This sale was conducted to satisfy tax withholding obligations related to restricted stock units that vested on May 23, 2026. Following this transaction, Tennant directly holds 139,369 common shares of PRECIGEN.
Precigen (PGEN) CFO sells 41,884 shares to cover RSU tax withholding
Precigen's Chief Financial Officer, Harry Thomasian Jr., sold 41,884 shares of common stock at $4.36 per share in a "sell-to-cover" transaction. This sale was conducted to satisfy tax withholding obligations triggered by the vesting of restricted stock units on May 23, 2026. Following this transaction, Thomasian Jr. directly holds 554,535 shares of Precigen common stock.
Precigen chief legal officer Lehr sells $127,011 in stock
Donald P. Lehr, Precigen's Chief Legal Officer, sold 29,131 shares of the company's common stock for a total of $127,011 to cover tax obligations from vested restricted stock units. Despite a 229% return over the past year, InvestingPro suggests the stock may be overvalued. However, analysts predict the company will be profitable this year, and recent reports show Precigen surpassed Q1 2026 earnings expectations and received orphan drug exclusivity for PAPZIMEOS.
Precigen CFO Harry Thomasian Jr. sells $182,614 in stock
Precigen CFO Harry Thomasian Jr. sold 41,884 shares of company stock for $182,614 to cover tax obligations related to vested restricted stock units. Despite this transaction, Thomasian Jr. still directly holds over half a million shares. The company recently surpassed Q1 2026 earnings expectations and received orphan drug exclusivity for its PAPZIMEOS treatment, highlighting significant progress.
Precigen CCO Phil Tennant sells $131,985 in stock
Precigen CCO Phil Tennant sold 30,272 shares of company stock worth $131,985 to cover tax withholding obligations after restricted stock units vested. Despite this sale, Precigen shares have surged 229% over the past year, and the company recently exceeded Q1 2026 earnings expectations and received orphan drug exclusivity for PAPZIMEOS. Tennant still directly holds 139,369 shares.
Precigen (PGEN) COO sells 42,703 shares to cover RSU tax withholding
Precigen's Chief Operating Officer, Rutul R. Shah, sold 42,703 shares of common stock at $4.36 per share on May 28, 2026. This transaction was a "sell-to-cover" sale to satisfy tax withholding obligations from restricted stock units that vested on May 23, 2026. Following the sale, Shah still holds a significant stake of 497,751 shares in the company.
Precigen (PGEN) Chief Legal Officer sells shares to cover RSU tax withholding
Precigen's Chief Legal Officer, Donald P. Lehr, sold 29,131 shares of common stock at $4.36 per share on May 28, 2026. This transaction was a "sell-to-cover" to satisfy tax withholding obligations arising from restricted stock units that vested on May 23, 2026. Following the sale, Lehr holds 755,461 shares of Precigen common stock.
Number of shareholders of Precigen Inc – BX:I5X
This article from TradingView provides a snapshot of the number of shareholders for Precigen Inc (BX:I5X). It's a short, data-focused piece indicating that the information is available by period, value, and change percentages. The site primarily serves as a financial data platform offering various market tools and information.
Precigen jumps after Q1 beat as Papzimeos launch momentum takes hold
The provided article content was "MSN", which is insufficient to generate a summary. The article title suggests that Precigen's stock is up after beating Q1 earnings expectations, possibly due to the launch momentum of a product called Papzimeos. Without the actual content, further summarization is not possible.
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
Precigen, Inc. announced new long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) for recurrent respiratory papillomatosis (RRP) at the 2026 ASCO Annual Meeting. The data show 83% of complete responders maintained their response for at least 36 months, with five patients showing ongoing responses beyond four years. PAPZIMEOS, the first and only FDA-approved therapy for adult RRP, recently received seven-year market exclusivity.
Precigen (PGEN) COO converts 90,000 RSUs to common shares in Form 4 filing
Precigen's Chief Operating Officer, Rutul R. Shah, converted 90,000 restricted stock units (RSUs) into common stock. This transaction is part of his equity compensation, following which he directly holds 540,454 shares of common stock and 90,000 RSUs. This activity reflects routine vesting and conversion, with no open-market purchases or sales reported.
Precigen (PGEN) CFO gains 87,500 shares from RSU vesting
Precigen's Chief Financial Officer, Harry Thomasian Jr., acquired 87,500 shares of common stock through the vesting of restricted stock units on May 23, 2026. This transaction was part of his compensation package and did not involve any open-market purchases or sales. Following this, he directly holds 596,419 common shares and 87,500 remaining RSUs, which will vest quarterly over the next three years.
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS
The FDA has granted orphan drug exclusivity to Precigen Inc.'s PAPZIMEOS for treating recurrent respiratory papillomatosis, securing market protection until August 14, 2032. This news follows a significant stock surge for Precigen, and analysts anticipate the company will become profitable this year with continued sales growth. PAPZIMEOS is the first FDA-approved treatment for this rare chronic disease.
PRECIGEN (PGEN) CCO Phil Tennant acquires 62,500 shares through RSU vesting
PRECIGEN's Chief Commercial Officer, Phil Tennant, acquired 62,500 common shares on May 23, 2026, through the vesting of restricted stock units (RSUs). Following this transaction, Tennant directly holds 169,641 common shares, with an additional 62,500 RSUs remaining that will vest in equal quarterly installments over the next three years. This event is a compensation-related acquisition rather than an open-market purchase or sale.
PRECIGEN (PGEN) CEO adds 250,000 shares through RSU vesting and exercise
PRECIGEN's President and CEO, Helen Sabzevari, increased her equity in the company by exercising 250,000 restricted stock units (RSUs) into common stock on May 23, 2026. Following this transaction, her direct holdings climbed to 3,888,122 shares, with an additional 250,000 RSUs remaining outstanding, scheduled to vest in equal quarterly installments over the next three years. This activity reflects a scheduled vesting process and not an open-market sale.
Precigen (PGEN) Secures Orphan Drug Status for Papzimeos Treatment
Precigen Inc (PGEN) has obtained orphan drug exclusivity from the FDA for its Papzimeos treatment for recurrent respiratory papillomatosis (RRP), granting it seven years of market protection. Despite this positive development, the company faces financial challenges, including a high price-to-sales ratio, poor profitability, and significant insider selling, suggesting potential overvaluation and risks for investors. The GF Score™ of 57/100 indicates moderate long-term return potential but highlights weaknesses in financial strength and profitability.
FDA grants orphan drug exclusivity for Precigen’s PAPZIMEOS By Investing.com
The FDA has granted orphan drug exclusivity to Precigen Inc.'s PAPZIMEOS for treating recurrent respiratory papillomatosis, securing market exclusivity until August 2032. This follows PAPZIMEOS's full FDA approval in August 2025 and a significant surge in Precigen's stock price and revenue. Analysts predict the company to become profitable this year with projected earnings per share of $0.06.
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
Precigen, Inc. announced that the FDA has granted orphan drug exclusivity for its therapy, PAPZIMEOS (zopapogene imadenovec-drba), for adults with recurrent respiratory papillomatosis (RRP). This exclusivity provides seven years of market protection in the US, effective through August 14, 2032. PAPZIMEOS is the first and only FDA-approved treatment for RRP, a rare and debilitating disease, and is already commercially available nationwide.
